Vitamin D (25-OH): Deficient, Insufficient, or Sufficient

What 25-hydroxyvitamin D is and what it represents

Vitamin D (25-hydroxy), or 25(OH)D, is the main storage form of vitamin D circulating in your blood. It is made in the liver after your skin or diet supplies raw materials, integrating inputs from both cholecalciferol (D3) and ergocalciferol (D2). Think of it as your vitamin D "bank account": the balance rises with sun exposure and dietary intake, and drifts down when your body uses more than you deposit. Rising levels generally reflect adequacy of supply, while persistently low levels can signal shortfalls that may affect calcium regulation, bone remodeling, and muscle function.

The two-step biology behind your vitamin D number

Your skin makes vitamin D when UVB light hits 7-dehydrocholesterol. Food helps too: fatty fish, fortified dairy or plant milks, and egg yolks contribute smaller amounts. Those inputs travel to the liver, which converts them into 25(OH)D — the form measured in blood because it is stable, with a half-life of about two to three weeks.

Next stop: the kidneys, where enzymes convert 25(OH)D into 1,25-dihydroxyvitamin D (calcitriol), the active hormone that helps the gut absorb calcium and phosphate, keeps parathyroid hormone (PTH) in check, and coordinates bone turnover. It is a feedback loop: low calcium nudges PTH up, which boosts the kidney's conversion step; when calcium is adequate, PTH eases. Importantly, 25(OH)D does not measure the active hormone 1,25-dihydroxyvitamin D — kidney conversion is separately regulated and requires PTH and kidney-function context to interpret fully.

Season, latitude, skin pigmentation, age, and clothing coverage all shift production. Darker skin has more melanin, which is protective but reduces UVB-driven vitamin D synthesis. Older skin makes less precursor. Higher body mass index is often linked to lower 25(OH)D, likely from volumetric dilution and storage in adipose tissue over a larger body pool. Acute illness and inflammation may transiently lower measured 25(OH)D through shifts in vitamin D–binding protein and fluid balance. And because most assays measure total 25(OH)D (bound plus free), changes in binding proteins can nudge results without reflecting a true change in tissue availability.

One further lab consideration: different tests do not always agree. Some immunoassays under-detect D2. High-dose biotin can interfere with certain methods. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) is considered the reference approach for accuracy and for distinguishing D2 from D3. Patterns over time and clinical context beat a single, isolated datapoint.

Low, sufficient, and high vitamin D

Reference intervals are built from population data. Expert groups do not fully agree on cutoffs, partly because outcomes vary with age, baseline health, and what is measured alongside 25(OH)D. The National Academy of Medicine has emphasized that levels around 20 ng/mL (50 nmol/L) meet the needs of most people for bone health, with clear deficiency below 12 ng/mL (30 nmol/L). The Endocrine Society has previously used 20 ng/mL as a deficiency threshold and considered higher levels sufficient for many, while more recent guidance leans away from one-size-fits-all targets and routine screening in low-risk adults. Most guidelines define deficiency below 12–20 ng/mL and sufficiency at or above 30 ng/mL; specific cutoffs vary by guideline and lab. Labs also differ in calibration and units — multiply ng/mL by 2.5 to convert to nmol/L.

Normal 25(OH)D

A result in the sufficient range reflects adequate substrate for the kidney's activation step and supports normal calcium absorption and bone remodeling. In people without documented deficiency, however, a "normal" result has not shown sweeping benefit in large randomized trials: the VITAL trial did not lower major cardiovascular events or overall cancer incidence in generally healthy adults. Some meta-analyses suggest a modest reduction in cancer mortality with vitamin D supplementation, though not incidence, and the signal is small. Pooled analyses indicate a modest reduction in acute respiratory infections with regular dosing, especially in those starting out deficient, but effects vary. The case for optimization is strongest in documented deficiency.

High 25(OH)D

Most high 25(OH)D results come from taking more vitamin D than the body needs over a sustained period. The body has safeguards, but consistently high levels can be associated with elevated calcium and, rarely, symptoms such as nausea or kidney stones. Calcium, PTH, and kidney function help tell the full story alongside the vitamin D number.

Less commonly, granulomatous diseases such as sarcoidosis increase conversion to the active hormone, which can cause high calcium even when 25(OH)D is not extreme. Lab artifacts are another consideration: some immunoassays can read falsely high if large amounts of biotin have been taken within a day of testing, and cross-reactivity differs by platform. When results seem out of sync with the rest of your labs or how you feel, confirmation by LC–MS/MS can be clarifying.

Low 25(OH)D

Low levels often trace back to low sun exposure, minimal dietary intake, or seasonality. Skin pigmentation plays a role: more melanin means less cutaneous production from the same sun exposure. So do latitude and clothing. Higher BMI generally correlates with lower 25(OH)D for a given intake and sun exposure, reflecting distribution into a larger body pool.

Absorption and metabolism matter too. Celiac disease, inflammatory bowel disease, pancreatic insufficiency, and post-bariatric surgery states can blunt absorption. Liver disease can reduce conversion to 25(OH)D. Certain medications — including some anti-seizure drugs, rifampin, and glucocorticoids — increase vitamin D breakdown via hepatic enzymes. Chronic kidney disease affects the activation step, so 1,25-dihydroxyvitamin D falls and PTH rises even when 25(OH)D is only mildly low.

Life stage can shift interpretation. Older adults synthesize less in skin. During pregnancy, binding proteins rise and active vitamin D increases, while total 25(OH)D may not change much, so context matters. In people with deficiency, improving status alongside adequate calcium supports bone mineralization and reduces osteomalacia in adults. A single low value is not a diagnosis; it is a flag to consider symptoms, related labs, and whether it persists on repeat testing.

Reasons your vitamin D drifts season to season

Several biological and environmental factors shift 25(OH)D independently of how much vitamin D you consciously consume or seek.

• UVB seasonality, latitude, and clothing: Cutaneous synthesis drops sharply in winter at northern latitudes and is further reduced by clothing coverage, indoor work, and sunscreen use. This is the dominant driver of the seasonal dip most people experience.
• Skin pigmentation: Melanin absorbs UVB, which is protective against UV damage but reduces the rate of vitamin D synthesis. People with darker skin require longer sun exposure to produce equivalent amounts of 25(OH)D.
• Body mass and adipose distribution: Higher BMI is associated with lower circulating 25(OH)D, likely because vitamin D is fat-soluble and distributes into a larger adipose pool, reducing the concentration measured in blood.
• Malabsorption conditions: Celiac disease, inflammatory bowel disease, pancreatic insufficiency, and post-bariatric surgery states reduce intestinal absorption of vitamin D from food and supplements.
• Hepatic 25-hydroxylation: Liver disease can impair the conversion of vitamin D precursors to 25(OH)D, lowering measured levels even when intake is adequate.
• Chronic kidney disease: CKD reduces the kidney's ability to convert 25(OH)D to the active hormone 1,25-dihydroxyvitamin D, causing PTH to rise even when 25(OH)D is only mildly low. A low 25(OH)D result in the context of CKD may reflect both storage shortfall and activation failure.
• Medications: Certain anti-epileptics, rifampin, and glucocorticoids accelerate vitamin D breakdown via hepatic enzymes, lowering 25(OH)D over time.
• Magnesium status: Magnesium is a cofactor for the hydroxylase enzymes that convert vitamin D to 25(OH)D and then to the active hormone. Chronically low magnesium can impair vitamin D metabolism and blunt supplementation response.
• Assay method and biotin interference: LC–MS/MS is the reference standard and distinguishes D2 from D3 accurately. Some immunoassays under-detect D2 or are susceptible to interference from high-dose biotin (above 5 mg/day), which can falsely elevate results. Acute illness and inflammation may also transiently lower measured 25(OH)D through shifts in vitamin D–binding protein.

Vitamin D and its companion biomarkers

25(OH)D is most informative when read alongside the markers that sit upstream and downstream in the same mineral-regulation pathway.

• Calcium — calcium is the primary downstream readout of vitamin D's action. Low 25(OH)D with falling calcium and rising PTH confirms secondary hyperparathyroidism from vitamin D shortfall, the clearest clinical signal that deficiency is affecting mineral balance.
• Magnesium — magnesium is a cofactor for the hydroxylase enzymes that convert vitamin D to 25(OH)D and then to the active hormone. Chronically low magnesium can impair vitamin D metabolism and blunt supplementation response, making it a useful check when 25(OH)D fails to rise as expected.
• eGFR — chronic kidney disease reduces 1,25-dihydroxyvitamin D production even when 25(OH)D is adequate. eGFR context determines whether a low value reflects a storage shortfall or an activation failure, which have different clinical implications.
• Vitamin K — vitamin K activates osteocalcin and matrix Gla-protein, the bone-calcium-directing proteins that depend on vitamin D for their substrate. Combined low D and low K creates a compounded bone-metabolism shortfall that neither marker fully captures alone.
• Alkaline phosphatase (ALP) — bone-isoenzyme ALP rises with increased bone turnover when vitamin D is very low. Elevated ALP alongside low 25(OH)D hints at the accelerated remodeling that precedes osteomalacia, adding clinical weight to an otherwise isolated low result.

Retesting vitamin D on a realistic timeline

25(OH)D has a half-life of roughly two to three weeks, and RCT data show that steady state after a supplement dose change is reached at approximately 8–12 weeks. Retesting sooner than that captures a moving target rather than a stable new baseline.

• After initiating or changing a supplement dose: retest at 12 weeks to assess the full response.
• Annual seasonal check: an end-of-winter draw is useful for anyone with risk factors — indoor work, northern latitude, darker skin, malabsorption, or medications that accelerate vitamin D breakdown — to catch the seasonal nadir before it becomes symptomatic.

For meaningful trend comparison, use the same laboratory and the same assay method across draws. LC–MS/MS is the reference standard; switching between immunoassay platforms can introduce apparent changes that reflect method differences rather than biology. A morning draw under consistent conditions reduces day-to-day variability. If you take biotin supplements above 5 mg/day, pause for at least 48 hours before the blood draw to avoid falsely elevated results on immunoassay-based platforms.

When a vitamin D result warrants follow-up

The U.S. Preventive Services Task Force has judged evidence insufficient to recommend routine screening in asymptomatic adults, so testing is most useful when there is a clinical question, a change in health status, or a need to monitor a plan. A result outside the sufficient range is a prompt to look at the full picture: symptoms, related markers (calcium, ALP, eGFR, magnesium), medications, and whether the pattern persists on repeat testing.

A very low result alongside elevated ALP, rising PTH, or falling calcium moves from a lab flag to a clinical finding that warrants discussion with a clinician — particularly in older adults, people with malabsorption, or those on medications that accelerate vitamin D breakdown. A high result, especially with elevated calcium, similarly warrants follow-up to rule out over-supplementation or a granulomatous condition driving excess activation.

Vitamin D shifts with seasons, habits, and health changes. Testing gives you a baseline and then a trend line — the difference between catching a seasonal dip early and discovering a prolonged shortfall after it has affected bone turnover. Pairing the number with calcium, eGFR, and magnesium lets you read the whole mineral-regulation system at once rather than a single isolated value. That is the approach to preventive health that Superpower is built around: comprehensive biomarker data, read in context, so you can make informed and personalized decisions with your care team. Learn more about our approach to preventive health.